Back

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound

Zacharopoulou, P.; Marchi, E.; Ogbe, A.; Robinson, N.; Brown, H.; Jones, M.; Parolini, L.; Pace, M.; Grayson, N.; Kaleebu, P.; Rees, H.; Fidler, S.; Goulder, P.; Klenerman, P.; Frater, J.

2020-11-24 microbiology
10.1101/2020.11.24.395574 bioRxiv
Show abstract

Although certain individuals with HIV infection can stop antiretroviral therapy (ART) without evidence of viral load rebound, the mechanisms under-pinning post-treatment control remain unclear. Twelve individuals who had received 12 months of ART from primary HIV infection and then undertook a TI were sampled at the time of stopping therapy. Using RNA-Seq we explored gene expression in CD4 T cells to look for evidence of a mechanism that might underpin virological rebound and lead to discovery of an associated biomarker. Using independent analysis tools, genes associated with the type I interferon response were strongly associated with a delayed time to viral rebound following TI. These are the first data we are aware of that link transcriptomic signatures associated with innate immunity with control following TI. While these results need to be confirmed in larger trials, they could help define a strategy for new therapies and identify new biomarkers for remission.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.